The UK Lipid lowering drug market size stood at around USD xx billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of XX% during the forecast period.
The UK market is the world’s most potential market for lipid-lowering drugs and one of the fastest-growing markets in the world. The market size of UK’s lipid-lowering drugs will continue to expand, and the growth rate will gradually increase. UK’s lipid-lowering drug industry structure imported drugs have long occupied a relatively high proportion of the market. The overall prevalence of dyslipidemia in Chinese adults is as high as 40.4%. The increase in the population’s serum cholesterol level will lead to an increase of approximately 9.2 million cardiovascular events from 2010 to 2030.
Growing prevalence of different cardiovascular diseases, which are caused by various factors such as increased obesity, changing food habits, higher alcohol consumption, and smoking is driving the cholesterol lowering drugs market. Growing awareness about bad cholesterol is one of the key drivers that is triggering the growth of the cholesterol lowering drugs market. Companies are referring investigational studies to understand which drugs are well-tolerated in patients and make improvements according to the results. Moreover, development of drug formulation for cholesterol lowering, new therapies such as emergence of PCSK9 inhibitors, and growing awareness about cardiovascular diseases are some of the major factors responsible for the growth of the cholesterol lowering drugs market. Lucrative opportunities in emerging economies are expected to provide significant prospects for the manufacturers in industry.